Apellis Pharmaceuticals Inc
APLS
Market Cap$2.19B
Close$
$-40.45
326.3% downside
Current Fair Value
326.3% downsideOvervalued by 326.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.19 Billion |
|---|---|
| Enterprise Value | $2.30 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.6 |
| Beta | 0.67 |
| Outstanding Shares | 125,453,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -9.78 |
|---|---|
| PEG | -25.17 |
| Price to Sales | 3.57 |
| Price to Book Ratio | 17.87 |
| Enterprise Value to Revenue | 3.13 |
| Enterprise Value to EBIT | -10.31 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 2.86 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Apellis Pharmaceuticals Inc
CEO: Cedric Francois